Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials

  title={Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials},
  author={Jack J. Chen and Yi Han and Jonathan Tang and Iv{\'a}n Burgos Portillo and Robert A. Hauser and Khashayar Dashtipour},
  journal={Annals of Pharmacotherapy},
  pages={1182 - 1194}
Background: The comparative effects of droxidopa and midodrine on standing systolic blood pressure (sSBP) and risk of supine hypertension in patients with neurogenic orthostatic hypotension (NOH) are unknown. Objective: To perform a Bayesian mixed-treatment comparison meta-analysis of droxidopa and midodrine in the treatment of NOH. Methods: The PubMed, CENTRAL, and EMBASE databases were searched up to November 16, 2016. Study selection consisted of randomized trials comparing droxidopa or… 

Management Strategies for Comorbid Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension

The pathophysiology and clinical characteristics of neurogenic orthostatic hypotension and neurogenic supine hypertension are reviewed, and a stepwise treatment approach is presented to help guide neurologists in managing patients with both nOH and nSH.

Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases

The authors review the effects of droxidopa in NOH with a focus on the neurodegenerative diseases PD, MSA, and pure autonomic failure (PAF, where results appear essentially similar) and indicates a positive yet short-lasting effect of the drug on OH Questionnaire composite score, light-headedness/dizziness score, and standing BP during the first two treatment-weeks.

Orthostatic Hypotension in Hypertensive Adults: Harry Goldblatt Award for Early Career Investigators 2021

Recent evidence suggests that intensive blood pressure control may reduce the risk of orthostatic hypotension, and a detailed characterization of blood pressure variability is essential to tailoring a treatment plan and can be accomplished using both in-office and out-of-office monitoring.

Orthostatic Hypotension in Older Adults

It is concluded that orthostatic hypotension is common in the elderly and increases with advancing age, and is associated with cardiovascular disease, particularly those manifestations measured objectively, such as carotid stenosis.

Role of nurses and nurse practitioners in the recognition, diagnosis, and management of neurogenic orthostatic hypotension: a narrative review

Neurogenic orthostatic hypotension (nOH) is a sustained reduction in blood pressure (BP) upon standing that is caused by autonomic dysfunction and is common among patients with a variety of

Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer

The pathophysiology and effects of Neurogenic orthostatic hypotension, a potentially serious manifestation of cardiovascular sympathetic failure that occurs in approximately 30% of patients with PD, are reviewed.

Neurogenic orthostatic hypotension with Parkinson's disease as a cause of syncope: A case report

Ambulatory blood pressure monitoring is a cost-effective method for its diagnosis, and non-pharmacological measures are still the primary management methods for syncope.

New horizons in the ageing autonomic nervous system: orthostatic hypotension and supine hypertension

The healthy barore Flex, and physiological and pathophysiological reasons for impaired baroreflex function in older people, are discussed, and strategies for balancing these conflicting priorities are discussed.

Orthostatic hypotension in older people: considerations, diagnosis and management.

In summary, orthostatic hypotension (and associated supine hypertension) are common, dangerous and disabling, but adherence to simple structures management strategies can result in major improvements.



Droxidopa for orthostatic hypotension: a systematic review and meta-analysis

Droxidopa is well tolerated and effective at reducing the symptoms associated with neurogenic orthostatic hypotension without increasing the risk of supine hypertension.

A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension

A 10-mg dose of midodrine prescribed two to three times daily is effective in increasing orthostatic blood pressure and ameliorating symptoms in patients with NOH.

Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).

This exploratory analysis of a small dataset failed to show benefit of droxidopa, as compared with placebo by the primary endpoint, but there were signals of potential benefit for nOH, including improvement in dizziness/lightheadedness and reduction in falls, meriting evaluation in further trials.

Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension

Droxidopa is a safe and effective drug for the short-term management of NOH symptoms, however, current evidence is insufficient to confirm the efficacy of droxidopa for long-term use.

Midodrine for Orthostatic Hypotension: A Systematic Review and Meta-Analysis of Clinical Trials

There is insufficient and low quality evidence to support the use of midodrine for OH, and there was a significant increase in risk of piloerection, scalp pruritis, urinary hesitancy/retention, supine hypertension and scalp paresthesia after giving midodine.

Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.

Midodrine is efficacious and safe in the treatment of neurogenic orthostatic hypotension and in the evaluable patients, midodrine resulted in improvements in standing systolic BP at all time points.

Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa

This randomized withdrawal droxidopa study failed to meet its primary efficacy end point and additional clinical trials are needed to confirm that droxIDopa is beneficial in symptomatic neurogenic orthostatic hypotension, as suggested by the positive secondary outcomes.

Droxidopa for the Short‐Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson's Disease (nOH306B)

Neurogenic orthostatic hypotension (nOH) results from failure of norepinephrine responses to postural change to maintain standing systolic blood pressure (s‐SBP). Droxidopa is an oral prodrug of

Droxidopa for neurogenic orthostatic hypotension

In patients with symptomatic nOH, droxidopa improved symptoms and symptom impact on daily activities, with an associated increase in standing systolic BP, and was generally well tolerated.